Chronic Lymphocytic Leukemia
Conditions
Keywords
Chronic Lymphocytic Leukemia, Leukemia, Venetoclax, Rituximab, Lymphoid, Lymphoproliferative Disorders, Antineoplastic Agents, Neoplasm
Brief summary
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Detailed description
The study has one arm and all the patients will receive venetoclax and rituximab.
Interventions
DRUGVenetoclax
Venetoclax will be administered as described in the reporting arm.
DRUGRituximab
Rituximab (IV) will be administered as described in the reporting arm.
DRUGRituximab/Hyaluronidase Human
Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
Sponsors
Georgetown University
Hackensack Meridian Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed Informed Consent Form * Ability and willingness to comply with the requirements of the study protocol * Patient must have diagnosis of CLL that meets published 2008 IWCLL NCI-WG criteria. * Patient must have relapsed/refractory disease with an indication for treatment. * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2 * Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator) defined as follows: * Hemoglobin (\> / =) 9 g/dL * Absolute neutrophil count (\> / =) 1.0 x 109/L * Platelet count (\> / =)75 x 109/L * Adequate renal function, as indicated by: * Calculated creatinine clearance ≥ 30 mL/min using 24-hour Creatinine Clearance or modified Cockcroft-Gault equation (eCCR; with the use of ideal body mass \[IBM\] instead of mass) * Adequate liver function, as indicated by: * AST or ALT (\< / =) 2.5 x ULN * Total bilirubin \< 1.5 x ULN (or (\< / =) 3 x ULN for patients with documented Gilbert syndrome) * Female patients who are not of child-bearing potential and female patients of child-bearing potential who have a negative serum pregnancy test within 3 days prior to Cycle 1, Day 1. * Patients with HIV infection could be included in the study, as long as their disease is under control on anti-retroviral therapy. Precautions should be taken to modify their HAART regimen to minimize drug interaction * Warfarin is considered a cautionary medication. Patients on warfarin will be encouraged to replace warfarin with other anticoagulants if possible. If it is not possible or patient is not willing to switch, they could still be included in the study with caution.
Exclusion criteria
* Known hypersensitivity to any of the study drugs * Allogeneic stem cell transplant within the past 1 year. * Richter's transformation confirmed by biopsy * History of other malignancy that could affect compliance with the protocol or interpretation of results * Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible. * Patients with a malignancy that has been treated with surgery alone with curative intent will be included. Individuals in documented remission without treatment for (\> / =) 2 years prior to enrollment may be included at the discretion of the investigator. * Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm) * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1 * Received the following agents within 7 days prior to the first dose of venetoclax: * Steroid therapy for anti-neoplastic intent * Strong and moderate CYP3A inhibitors * Strong and moderate CYP3A inducers * Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax * Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis * Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody * Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation * Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody \[HBcAb\] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing. * Known infection with human T-cell leukemia virus 1 (HTLV-1) * Patients with uncontrolled HIV infection * Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment * Pregnant or lactating, or intending to become pregnant during the study Women of childbearing potential must have a negative serum pregnancy test result within 21 days prior to initiation of study drug. * Recent major surgery (within 6 weeks prior to the start of Cycle 1, Day 1) other than for diagnosis * Malabsorption syndrome or other condition that precludes enteral route of administration * Known allergy to both xanthine oxidase inhibitors and rasburicase
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) | Percentage of Participants With Best Overall Response (OR)(Defined as Complete Response \[CR\], Initial CR \[CRi\], Nodular Partial Response \[nPR\], PR) as Assessed by Investigator Determined Using iwCLL Guidelines |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease Response | 12 weeks after Day 1 of last cycle of combination therapy (approximately 5 years, cycle length= 28 days) | Percentage of Participants With Disease Response (OR, CR, CRi, nPR, PR) as Assessed by Investigator Determined Using iwCLL Guidelines at end of Combination Treatment Visit |
| Duration of Responses (DOR) | Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) | Duration of Responses (DOR) |
| Time to Progression (TTP) | Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) | Time to progression will be defined as the time from the date of first dose (date of enrollment if not dosed) to the date of earliest disease progression (per the investigator assessment). |
| Progression-Free Survival (PFS) | Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ] | Investigator-Assessed Progression-Free Survival (PFS) Determined Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines |
| Overall Survival (OS) | Baseline up to death (up to approximately 5 years) | Overall Survival (OS) |
| Time to Next Anti-CLL Treatment (TTNT) | Baseline up to disease progression or death, whichever occurs first (up to approximately 5 years) ] | Time to Next Anti-CLL Treatment (TTNT) |
| Percentage of Participants With Minimal Residual Disease (MRD) | 12 weeks after Day 1 of last cycle of combination therapy (up to approximately 5 years, cycle length= 28 days) ] | Percentage of Participants With Minimal Residual Disease (MRD) Negativity at End of Combination Treatment Response Visit |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKieron Dunleavy, MD
Georgetown University
Outcome results
None listed